As of May 25, 2025, Midatech Pharma PLC has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $3.75, this represents a potential upside of -19889.9%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -20910.4% |
| Potential Upside (10-year) | -19889.9% |
| Discount Rate (WACC) | 5.5% - 8.0% |
Revenue is projected to grow from $1 million in 12-2021 to $1 million by 12-2031, representing a compound annual growth rate of approximately 0.0%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2021 | 1 | 69% |
| 12-2022 | 1 | 5% |
| 12-2023 | 1 | 3% |
| 12-2024 | 1 | 2% |
| 12-2025 | 1 | 2% |
| 12-2026 | 1 | 5% |
| 12-2027 | 1 | 2% |
| 12-2028 | 1 | 2% |
| 12-2029 | 1 | 3% |
| 12-2030 | 1 | 2% |
| 12-2031 | 1 | 2% |
Net profit margin is expected to improve from -945% in 12-2021 to -720% by 12-2031, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2021 | (5) | -945% |
| 12-2022 | (6) | -575% |
| 12-2023 | (6) | -591% |
| 12-2024 | (6) | -603% |
| 12-2025 | (6) | -615% |
| 12-2026 | (6) | -645% |
| 12-2027 | (7) | -658% |
| 12-2028 | (7) | -671% |
| 12-2029 | (7) | -692% |
| 12-2030 | (7) | -706% |
| 12-2031 | (7) | -720% |
. Projected CapEx is expected to maintain at approximately 43% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2022 | 0 |
| 12-2023 | 0 |
| 12-2024 | 0 |
| 12-2025 | 0 |
| 12-2026 | 0 |
| 12-2027 | 0 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 220 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2022 | (7) | (1) | 0 | 1 | (8) |
| 2023 | (7) | (1) | 0 | (0) | (7) |
| 2024 | (7) | (1) | 0 | 0 | (7) |
| 2025 | (8) | (1) | 0 | 0 | (7) |
| 2026 | (8) | (1) | 0 | (0) | (7) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -20910.4% |
| 10-Year DCF (Growth) | 0.00 | -19889.9% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Midatech Pharma PLC (MTPH.L) a buy or a sell? Midatech Pharma PLC is definitely a sell. Based on our DCF analysis, Midatech Pharma PLC (MTPH.L) appears to be overvalued with upside potential of -19889.9%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $3.75.